Table 4.

Reasons for discontinuation

Variables	All (n = 167)	Previous biologics		Concomitant MTX
		(+) (n = 49)	(–) (n = 119)	(+) (n = 144)	(–) (n = 24)
Total	55	25	30	42	13
Lack of efficacy	24	14	10	16	8
Adverse events	16	9	7	13	3
Efficacy	5	0	5	4	1
Other reasonsa	10	2	8	9	1

Two drop-outs with unknown discontinuation date were included. Those who discontinued after 52 weeks of treatment were also included

^aOther reasons include patient’s choice and eye surgery